Chlorogen Inc.
This article was originally published in Start Up
Executive Summary
Inserting foreign genes into chloroplasts--the compartments within plant cells where photosynthesis occurs--may have significant advantages over other transgenics technologies for producing therapeutic proteins. Chlorogen Inc. believes its proprietary chloroplast transformation technology will make the St. Louis start-up a player in the protein production arena.
You may also be interested in...
Protein Production Start-Ups
Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.